

MAR 14 2006

Attorney Docket No.: 5636.210-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Nielsen et al.

Confirmation No: 6089

Serial No.: 10/038,723

Group Art Unit: 1652

Filed: December 21, 2001

Examiner: Rao

For: Glucoamylase Variants

**CERTIFICATE OF FACSIMILE TRANSMISSION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment Fee Transmittal
2. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Rao, fax number (571) 273-0939.

Respectfully submitted,



Date: March 14, 2006

Lourdes Ayala  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

**RECEIVED**  
**CENTRAL FAX CENTER**

**MAR 14 2006**

Attorney Docket No.: 5636.210-US

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Nielsen et al.

Confirmation No: 6089

Serial No.: 10/038,723

Group Art Unit: 1652

Filed: December 21, 2001

Examiner: Rao

For: Glucoamylase Variants

**AMENDMENT FEE TRANSMITTAL**


Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is an Amendment for the above-identified application  
No additional claims or extension fees are required.

Respectfully submitted,

Date: March 14, 2006

  
\_\_\_\_\_  
Jason A. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097

MAR 14 2006

Attorney Docket No.: 5636.210-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Nielsen et al.

Confirmation No: 6089

Serial No.: 10/038,723

Group Art Unit: 1652

Filed: December 21, 2001

Examiner: Rao

For: Glucoamylase Variants

**AMENDMENT UNDER 37 C.F.R. 1.111**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Please amend the above-identified application as follows:

**Amendments to the claims** are reflected in the listing of claims, which begins on page 2 of this document.

**Remarks and arguments** begin on page 7 of this document.